Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE We used long-read, deep-sequenced data of full-length HCV envelope glycoprotein, longitudinally sampled from acute to chronic HCV infection to investigate the underlying viral population and evolutionary dynamics. 30602023 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE In the present study, we constructed genetic vaccines based on novel recombinant adeno‑associated viral (rAAV) vectors (AAV2/8 or AAV2/rh32.33) that express the envelope glycoprotein E2 from the HCV genotype 1b. 30569131 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Our phase I study with recombinant HCV E1/E2 envelope glycoprotein (EnvGPs) as a candidate vaccine did not induce a strong immune response in volunteers. 29443378 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE Overall, statistically significant associations were found between HCV quasispecies diversity, selective pressure exerted on the HCV E2 envelope protein, and neutralizing activity of maternal immunoglobulins. 30365007 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE Assembly of infectious hepatitis C virus (HCV) particles is known to involve host lipoproteins, giving rise to unique lipo-viro-particles (LVPs), but proteome studies now suggest that additional cellular proteins are associated with HCV virions or other particles containing the viral envelope glycoprotein E2. 30880226 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE NS2 also promotes HCV particle assembly by recruiting envelope protein 2 (E2) to the virus assembly sites located at the detergent-resistant membranes (DRM). 31597774 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression disease BEFREE Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus. 31116791 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Overcoming Challenges of Hepatitis C Virus Envelope Glycoprotein Production in Mammalian Cells. 30593635 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE However, this effort has proven challenging because HCV evades neutralizing antibodies (NAbs) through molecular features of viral envelope glycoprotein E2, including hypervariable region 1 (HVR1) and N-linked glycans. 31040211 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Cumulative evidence supports the importance of antibodies targeting the HCV E2 envelope glycoprotein to facilitate viral clearance. 30651366 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Herein, we evaluated two different semi-synthetic archaeosome formulations as an adjuvant to the E1/E2 HCV envelope protein in a murine model and compared antigen-specific humoral (levels of anti-E1/E2 IgG and HCV pseudoparticle neutralization) and cellular responses (numbers of antigen-specific cytokine-producing T cells) to those generated with adjuvant formulations composed of mimetics of commercial adjuvants including a squalene oil-in-water emulsion, aluminum hydroxide/monophosphoryl lipid A (MPLA) and liposome/MPLA/QS-21. 31816920 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE The high variation in envelope protein sequence among HCV isolates necessitates the inclusion of several isolates, spanning the major genotypes of HCV, in order to make strong conclusions concerning the cross-reactive neutralization potential of a given antibody. 30593643 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE This is a sensitive and robust method for future studies investigating B cell responses against the HCV Envelope protein. 31226262 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein. 29951061 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE Peterson, F. Gavilanes, Structural properties of the ectodomain of hepatitis C virus E2 envelope protein, Virus Res.139 (2009) 91-99). 29273334 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE NEURL3 inhibits HCV assembly by directly binding viral E1 envelope glycoprotein to disrupt its interaction with E2, an action that requires its Neuralized homology repeat (NHR) domain but not the RING domain. 30111563 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Hepatitis C virus (HCV) envelope glycoprotein heterodimer, E1E2, plays an essential role in virus entry and assembly. 29755477 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE In summary, mAb A6 is an important tool to study the structure and function of E1 within the viral envelope, a crucial step in the development of an effective prophylactic HCV vaccine. 29128754 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Molecular basis of benzimidazole inhibitors to hepatitis C virus envelope glycoprotein. 29745064 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Interestingly, the inhibition of autophagy by ATG7 knockdown reduced the colocalization of ApoE with the HCV E2 envelope protein and the HCV titers released from cells. 29695434 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Using the structure of a broadly neutralizing antibody in complex with a conserved linear epitope from the HCV E2 envelope glycoprotein (residues 412 to 423; epitope I), we performed structure-based design of immunogens to induce antibody responses to this epitope. 28794021 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE In this study, we rescued a recombinant PR8 influenza viral vector, called rgFLU-HCV<sub>CE1E2</sub>, carrying the core and envelope glycoprotein (C/E1/E2) epitopes of HCV inserted into the influenza nonstructural protein 1 gene. 28778831 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Hepatitis C virus (HCV) envelope glycoprotein complex is composed of E1 and E2 subunits. 28179528 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE The occurrence of five sense mutations [S391A, G397A, L402F and M405T in the hypervariable region 1 (HVR1) of envelope glycoprotein 2 and I2750M in NS5B] suggested that HCV undergoes genetic evolution during culture. 28758632 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE The dynamic properties of the Hepatitis C Virus E2 envelope protein unraveled by molecular dynamics. 26973093 2017